Ex) Article Title, Author, Keywords
Ex) Article Title, Author, Keywords
Pharmacoepidemiology and Risk Management 2024; 16(1): 18-28
Published online March 31, 2024 https://doi.org/10.56142/perm.24.0004
Copyright © Korean Society for Pharmacoepidemiology and Risk Management.
Su Jeong Song1,2, Hye-Ryun Kang1,2,3, Ji-Hyang Lee1,2
송수정1,2, 강혜련1,2,3, 이지향1,2
Correspondence to:Ji-Hyang Lee
Drug Safety Center, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel: +82-2-2072-1476
Fax: +82-2-2072-3644
E-mail: 83697@snuh.org
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Penicillin allergy labels are associated with significant challenges, including antimicrobial resistance, restricted prescribing options, and negative outcomes for both patients and health care systems. However, only 10% of individuals labeled as penicillin allergic are found to be truly allergic after formal assessment. The evaluation process for a penicillin allergy encompasses a detailed allergy history, often followed by skin testing, and drug challenge. Researchers have suggested assessment tools and clinical decision rules for risk stratification for efficient and precise removal of incorrect penicillin allergy labels. In particular, patients categorized as low risk based on the assessment may undergo direct challenge test with penicillin, a practice supported by accumulating evidence. This comprehensive approach, emphasizing history taking and risk stratification, highlights the important role of healthcare providers in reducing the burden related to penicillin allergy labels. This review aims to understand the process of penicillin allergy evaluation and potential benefits of delabeling.
KeywordsPenicillin allergy, Delabeling, Allergy assessment, Risk stratification, Drug challenge